Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

29,373 total articles

Nikita Bier Exits Product Lead Role at X After Just Over a Year

Nikita Bier Exits Product Lead Role at X After Just Over a Year

Nikita Bier has stepped down as head of product at X after a tenure of slightly more than a year. He will continue to advise the company after overseeing the roll-out of 30 new products and framing efforts to preserve what he called the "integrity of the town square." His departure comes amid controversies involving the platform's Grok chatbot and …

Nintendo Q1 Preview: Switch 2 Momentum Tested by Soaring Memory Prices

Nintendo Q1 Preview: Switch 2 Momentum Tested by Soaring Memory Prices

Nintendo reports first-quarter results for fiscal 2027 on Aug 6, with consensus estimates at ¥440.75 billion in revenue and ¥64.54 EPS. Investors will be watching whether sales momentum behind Switch 2 is sufficient to withstand a substantial increase in memory-chip costs, a factor that has pressured margins amid a market valuation that is -44.63% …

Duolingo Shares Slide After Revenue Guidance Comes Up Short

Duolingo Shares Slide After Revenue Guidance Comes Up Short

Duolingo reported stronger-than-expected second-quarter operating metrics and adjusted earnings, but a Q3 revenue forecast and updated full-year guidance that slightly trailed analyst estimates sent the stock sharply lower in after-hours trading. Management emphasized user growth over near-term monetization, while an earlier analyst downgrade added…

FDA Clears Takeda’s First-in-Class Oral Therapy for Narcolepsy Type 1

FDA Clears Takeda’s First-in-Class Oral Therapy for Narcolepsy Type 1

The U.S. Food and Drug Administration has approved Takeda Pharmaceutical’s oral medication for narcolepsy type 1, marking the first approved therapy to directly address the orexin deficiency that underlies the disorder. The decision relied on clinical trials showing daytime wakefulness improvements versus placebo. Final U.S. patient access will dep…

News Corp Tops Q4 Revenue Estimates on Strength in Digital Real Estate, Books and Dow Jones Subscriptions

News Corp Tops Q4 Revenue Estimates on Strength in Digital Real Estate, Books and Dow Jones Subscriptions

On Aug 5, News Corp reported fourth-quarter results that exceeded revenue forecasts, driven by gains in digital real estate services, book publishing and its Dow Jones subscription business. The company recorded $2.34 billion in revenue, beating consensus estimates, and posted adjusted earnings per share of $0.35, nearly double the prior-year figur…

APA Posts Q2 Beat as Crude Strength Outweighs Lower Output

APA Posts Q2 Beat as Crude Strength Outweighs Lower Output

APA Corp. reported a second-quarter adjusted profit slightly above analyst expectations as a rise in crude prices offset a decline in volumes. The company cited higher realized oil prices, expanded cost-savings targets and continued debt paydown while trimming quarterly production across several regions.

Colombian equities retreat as COLCAP closes down 1.26%

Colombian equities retreat as COLCAP closes down 1.26%

Colombian stocks ended lower after the close on Wednesday, with the COLCAP index sliding 1.26%. Sector declines in Financials, Investment and Public Services pressured the market, while individual names produced divergent results. Commodities and currency pairs also registered notable moves during the session.